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1. Introduction 
To maintain the integrity of the genome, cells have evolved a complex set of pathways that 
function in response to DNA damage. Components of this response include (i) cell cycle 
checkpoints that prevent damaged DNA from being replicated, (ii) induction of 
programmed cell death to prevent the transmission of potentially mutagenic genetic 
changes and (iii) DNA repair pathways that remove various types of DNA lesions such as 
single base lesions, single strand breaks (SSB)s or double strand breaks (DSB)s.   
DSBs are considered the most lethal form of DNA damage because, unlike almost any 
other types of DNA damage that have an intact undamaged template strand to guide the 
repair, the integrity of both strands of the duplex is lost (Khanna and Jackson, 2001). DSBs 
can be induced by environmental factors such as ionizing radiation, ultraviolet light, 
therapeutic treatment but also occur as a consequence of specific physiological processes 
such as DNA replication, the V(D)J recombination in B and T-lymphocytes or the 
immunoglobulin class switch recombination (CSR) within immunoglobulin variable 
domains in B-lymphocytes occurring during the development and maturation of the 
immune system (Ferguson and Alt, 2001, Revy et al., 2005). In order to maintain the 
integrity of the DNA information, cells recruit stringent DSB repair machinery to ensure 
the efficient repair of various types of DNA damage. Thus, failure to properly repair the 
DSBs may cause chromosomal abnormalities, which in turn, may lead to genomic 
instability and predispose the cells to malignant transformation. Moreover, the 
importance of DNA repair in protecting against DSB-induced genomic instability is 
suggested by the increased incidence of cancer in autosomal recessive DNA repair 
deficient human syndromes, such as BRCA1/2 deficient breast cancers (Futreal et al., 1994). 
Thus, since genomic instability is a common characteristic of both inherited and sporadic 
forms of cancer cells, it is likely that abnormalities in DNA repair contribute to the 
development and progression of sporadic cancers (Khanna and Jackson, 2001).  
DSBs can be repaired by two major pathways, homology–directed repair (HR) and non-
homologous end-joining (NHEJ) (Helleday et al., 2007). HR is active during the late S and 
G2 phases of the cell cycle and uses the intact sister chromatid as the template for repair 
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(Khanna and Jackson, 2001, Hartlerode and Scully, 2009). This pathway is a highly 
efficacious and error-free form of repair and is mainly responsible for the repair of DSBs 
caused by stalled/or collapsed replication forks induced for example by chemotherapeutic 
agents that abrogate DNA replication (Keller et al., 2001). HR mechanisms and their 
implication in genomic stability are reviewed in detail in Khanna and Jackson, 2001, 
Helleday et al., 2007, Hartlerode and Scully, 2009.  
NHEJ repairs DSBs quite differently from HR by joining DNA ends directly. This form of 
repair is independent of extensive DNA sequence homology, and therefore errors can be 
introduced during the processing and joining of non-compatible DNA ends (Khanna and 
Jackson, 2001, Lieber, 2008, Hartlerode and Scully, 2009). NHEJ occurs throughout the cell 
cycle and is the major DSB repair pathway in G0, G1 and early S phase. NHEJ is the 
preferential pathway for repair of DSBs in mammalian cells (Lieber et al., 2003, Lieber, 
2008).  
Here, we describe the mechanism(s) and the role(s) of the error-prone NHEJ pathway in the 
maintenance of genomic instability in cancer and discuss how targeting NHEJ is a 
promising therapeutic strategy in cancer.  
2. Error-prone NHEJ pathway: Mechanisms and properties in normal and 
cancer cells 
Classical or C-NHEJ contributes to the repair of DSBs caused by endogenous and exogenous 
DNA damaging agents and also plays an important role in the repair of programmed DSBs 
in normal mammalian cells, made during V(D)J or CSR (Lieber et al., 2006). In addition, 
evidence now exists for an alternative version of NHEJ (ALT-NHEJ) (Nussenzweig and 
Nussenzweig, 2007) that exists at low levels in normal cells (Sallmyr et al., 2008b) and is 
enhanced in the absence of C-NHEJ. Here, we discuss the mechanisms and properties of  
C-NHEJ and ALT-NHEJ in normal and cancer cells.  
2.1 The C-NHEJ pathway  
There appears to be two phases of C-NHEJ: a rapid phase and a slower phase (Riballo et al., 
2004). The rapid phase will repair most of the simple lesions which do not require any type 
of processing. In contrast,  the slower phase of NHEJ reflects both the repair of (i) DSBs that 
occur in condensed chromatin and (ii) more complex DSBs that require processing before 
ligation (Riballo et al., 2004, Goodarzi et al., 2008).  
The C-NHEJ pathway is initiated by the Ku70/Ku86 heterodimer also called Ku, a ring 
shaped complex that binds DSBs (Walker et al., 2001). This leads to the recruitment of the 
catalytic subunit of DNA dependent protein kinase (DNA PKcs) (Mimori and Hardin, 1986, 
Falzon et al., 1993, Gottlieb and Jackson, 1993) to form the activated DNA PK (Calsou et al., 
1999, Singleton et al., 1999). The kinase activity of DNA PK is critical for C-NHEJ (Lees-
Miller et al., 1990). DNA PK also phosphorylates other proteins, such as Artemis, which 
binds to DNA PKcs (Ma et al., 2002), activating its endonuclease activity at both 3’ and 5’ 
overhangs. The physical juxtaposition of DNA ends involves interactions between DNA-
bound DNA PKcs molecules (Yaneva et al., 1997, DeFazio et al., 2002). If DNA ends can be 
directly ligated then the repair only requires ligation by XLF/DNA ligase IV/XRCC4, after 
interaction with DNA PK (Ahnesorg et al., 2006, Buck et al., 2006). However, a large fraction 
of DSBs generated by agents such as, ionizing radiation, are not directly ligatable, and 
require additional processing (Chen et al., 2000, Lobrich and Jeggo, 2005). Many proteins are 
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involved in processing these DNA ends, including polynucleotide kinase (PNK) which 
interacts with XRCC4 (Chappell et al., 2002), the nucleases Flap endonuclease-1 (FEN-1) 
(Wu et al., 1999) and Artemis (Chen et al., 2000), and the Polymerase X family members, Pol 
µ and λ (Ma et al., 2004). As a consequence of these processing reactions, the joining of DSBs 
by C-NHEJ often results in the loss or addition of a few nucleotides and the presence of 
short complementary sequences, microhomologies, at the break site that presumably 
contribute to the alignment of the DNA ends (Roth et al., 1985, Roth and Wilson, 1986).   
A schematic of the C-NHEJ is presented in Figure 1.  
 
 
Fig. 1. In normal cells (upper panel), ALT-NHEJ pathway is a minor DSB repair pathway 
compared with C-NHEJ. In cancer cells (lower panel), the steady state levels of key C-NHEJ 
proteins are reduced whereas the steady state levels of key ALT-NHEJ are increased. This 
results in increased activity of the ALT-NHEJ pathway and reduced activity of the C-NHEJ 
pathway. Figure modified from Rassool and Tomkinson, 2010. 
2.2 The ALT-NHEJ pathway  
There are several lines of evidence for an alternative or back-up version of NHEJ that is 
enhanced in the absence of C-NHEJ (Riballo et al., 2004, Wang et al., 2006, Nussenzweig and 
Nussenzweig, 2007) (Figure 1). While these studies have begun to define more precisely the 
characteristics, mechanisms, regulation and roles of ALT-NHEJ in the development and 
maintenance of cancer, much of this pathway(s) remains to be elucidated. In the next 
section, the current state of our knowledge of ALT-NHEJ will be discussed.  
2.2.1 Key signatures of ALT-NHEJ 
The key features of the ALT-NHEJ pathway are that the repair junctions are characterized 
by larger deletions, insertions, and longer tracts of microhomology compared with those 
generated by C-NHEJ, and a much higher frequency of chromosomal translocations 
(Nussenzweig and Nussenzweig, 2007). 
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2.2.1.1 Microhomologies  
Mechanistically, 3’ single stranded overhangs containing longer tracts of microhomology 
are used to mediate ALT-NHEJ  (Corneo et al., 2007, Yan et al., 2007, Bennardo et al., 2008, 
Deriano et al., 2009, Dinkelmann et al., 2009, Rass et al., 2009, Xie et al., 2009). This 
generally involves the loss of the intervening DNA sequences between the 
microhomology containing regions, resulting in larger DNA deletions. The regions of 
microhomology always reside at the precise site of repair and can be used as a marker to 
define these repair events. Moreover, while, ALT-NHEJ is associated with the generation 
of 3’ single stranded overhang at the sites of DSBs, the presence of the DNA end-
processing factor CtlP, appears to be required for microhomology-mediated joins upon 
depletion of the C-NHEJ component Ku70 (Lee-Theilen et al., 2011). Notably, 
microhomology sequences suggestive of ALT-NHEJ have been found at the 
recombination junctions of radiation-induced genomic rearrangements (Morris and 
Thacker, 1993, Nohmi et al., 1999) implying that radiation-induced DSBs can be repaired 
by ALT-NHEJ. Moreover, microhomologies are frequently detected at the breakpoints of 
chromosomal deletions and translocations in human cancer cells (Canning and Dryja, 
1989, Dryja et al., 1989, Smanik et al., 1995, Wiemels and Greaves, 1999).  
2.2.1.2 Translocation frequency 
Several groups have observed that in the absence of C-NHEJ proteins, chromosomal 
translocations occur with increased frequency (Boboila et al., 2010b, Simsek and Jasin, 2010). 
These authors thus suggested that C-NHEJ suppresses chromosomal translocations. An 
alternative explanation for the increase in translocation frequency when C-NHEJ is absent, is 
that end-joining may be inefficient due to missing or mutant NHEJ components, and this 
may lead to the accumulation of multiple unrepaired DSBs. There is evidence that the repair 
kinetics of ALT-NHEJ is slower than that of C-NHEJ, in that end-joining assays performed 
in cells lacking DNA ligase IV are about 10 times slower than in cells proficient for C-NHEJ 
(Yan et al., 2007, Han and Yu, 2008). Thus, slowed NHEJ would be expected to increase the 
time of overlap during which two breaks would remain unrepaired, thereby increasing the 
chance of translocation events (Lieber, 2010).  
Recent studies have suggested that oncogenes critical in the pathogenesis of leukemias 
directly or indirectly down regulate steady state levels of key C-NHEJ proteins, and  
in concert, upregulate key ALT-NHEJ proteins, leading to an increase in the  frequency  
of deletions and translocations, which likely drive genomic instability, disease progression 
or resistance to treatment (Chen et al., 2008, Sallmyr et al., 2008b, Fan et al., 2010, Li et  
al., 2011).  
2.2.2 Components involved in ALT-NHEJ 
The presence or absence of Ku at the DSB dictate whether repair occurs via C-NHEJ or ALT-
NHEJ, respectively (Fattah et al., 2010, Cheng et al., 2011). Several DNA repair proteins have 
been implicated in ALT-NHEJ repair. These include, DNA ligase IIIα/XRCC1, poly(ADP) 
ribose polymerase-1 (PARP-1), the MRN complex (Mre11/Rad50/Nbs1), WRN and CtlP 
(Audebert et al., 2004, Wang et al., 2005, Wang et al., 2006, Rass et al., 2009, Robert et al., 
2009, Xie et al., 2009, Lee-Theilen et al., 2011, Cheng et al., 2011, Zhang and Jasin, 2011). 
Given that ALT-NHEJ is initiated by resected DNA ends, the question arises, which factors 
can bind resected DSBs to start this repair process? Recent work identified PARP-1 as an 
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additional potential contributor to ALT-NHEJ (Audebert et al., 2004). PARP-1 recognizes 
DNA strand interruptions in vivo and triggers its own modification as well as that of other 
proteins by the sequential addition of ADP-ribose to form polymers. PARP-1 intervenes in 
base excision and single strand annealing (SSA) and now also operates in ALT-NHEJ 
(Audebert et al., 2004, Wang et al., 2006). While its role in ALT-NHEJ remains to be clearly 
elucidated, Wang et al. showed that PARP-1 binds to DNA ends in direct competition with 
Ku (Wang et al., 2006). When essential components of C-NHEJ are absent, PARP-1 is 
recruited for DSB repair, particularly in the absence of Ku proteins (Wang et al., 2006, Cheng 
et al., 2011).  
The next question that arises is, which factor(s) is involved in the final joining reaction of 
ALT-NHEJ? Several studies implicate DNA ligase IIIα in ALT-NHEJ (Audebert et al., 2004, 
Wang et al., 2005, Haber, 2008). For example, using extract fractionation studies, Wang et al., 
showed that the majority of DNA end joining activity in extracts of HeLa cells could be 
attributed to DNA ligase IIIα (Wang et al., 2005). In addition, immunodepletion of DNA 
ligase IIIα from cell extracts caused loss of activity that could be recovered by the addition of 
the joining activity contributed by the purified enzyme. These experiments also ruled out a 
significant contribution to the end joining activity by DNA ligase I and DNA ligase IV. 
Furthermore, Wang et al., also addressed this question using RNA interference to 
investigate the requirements for DNA ligase IIIα and DNA ligase IV in the repair of DSBs 
(Wang et al., 2005). In vivo plasmid assays showed that DNA ligase IV-deficient mouse 
embryonic fibroblasts (MEFs) retained significant DNA end joining activity that could be 
reduced by up to 80% in cells knocked down for DNA ligase IIIα using RNAi (Wang et al., 
2005). These in vivo observations are in line with DNA ligase IIIα being a candidate 
component for ALT-NHEJ. Other studies have implicated additional factors in ALT-NHEJ, 
such as PNK, FEN-1 (Gottlich et al., 1998, Wang et al., 2003, Audebert et al., 2004, Wang et 
al., 2006), and it is expected that additional factors will also be identified in the future 
(Figure 1).  
2.2.3 Where ALT-NHEJ fits into the hierarchy of DSB repair? 
While there is strong evidence that ALT-NHEJ is enhanced in cells that are defective for C-
NHEJ, the question of where ALT-NHEJ fits into the hierarchy of DSB repair with respect to 
the cell cycle, and what would be the consequences of this repair at the genomic level, are 
still relatively unclear (Figure 2). 
2.2.3.1 ALT-NHEJ and cell cycle 
While it is well documented that HR is efficiently carried out only in the late S and G2 phases 
of the cell cycle using the newly synthesized sister chromatid, whereas C-NHEJ is the major 
DSB repair pathway in G0, G1 and early S phase (Lieber et al., 2003, Lieber et al., 2006), recent 
studies suggest that ALT-NHEJ may also be cell cycle dependent. During DNA replication, the 
newly replicated chromatids are held together by cohesin and this sister chromatid cohesion is 
maintained until mitosis. When a DSB occurs, the intact sister chromatid is preferentially used 
to repair the DSB by HR. If HR is defective, as it is demonstrated in BRCA 1/2 deficient 
cells, DSB is likely to be repaired by the following error-prone pathways (Tutt et al., 2001, 
Venkitaraman, 2001): (i) SSA that generates intrachromosomal deletions between repeated 
sequences, (ii) C-NHEJ pathway that generates small intrachromosomal deletions and 
insertions, and (iii) ALT-NHEJ pathway that generates larger deletions and chromosomal 
translocations. One of the roles of the DNA PK complex assembled on the DNA end is to 
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protect the DNA end from resection (Huertas, 2010). If C-NHEJ is defective, it is likely that 
end resection will occur (Figure 2). While the above hypothetical scenarios for error-prone 
repair of DSBs are envisioned, recent studies suggest that ALT-NHEJ may occur more 
frequently in G2. Mladenov and Iliakis enquired whether ALT-NHEJ was cell cycle 
dependent. In this study, MEFs with defects in C-NHEJ and/or HR were irradiated, G1 and 
G2 cells were isolated by cell sorting, and repair was examined by using pulse field gel 
electrophoresis (Mladenov and Iliakis, 2011). They found that wild-type and HR defective 
(Rad54-/-) MEFs repaired DSBs with similar efficiency in G1 and G2 phases. In contrast, C-
NHEJ defective (DNA ligase IV-/-, DNA PKcs-/-, and Ku70-/-) MEFs showed a more 
pronounced repair defect in G1 phase than in G2 phase. Importantly, DNA ligase IV-/-/Rad54-
/- MEFs repaired DSBs as efficiently as DNA ligase IV-/- MEFs in G2 suggesting that the 
increased repair efficiency in G2 phase relies on the enhanced function of ALT-NHEJ rather 
than on HR. Furthermore, in vivo and in vitro plasmid end joining assays confirmed an 
enhanced function of ALT-NHEJ in G2 phase (Mladenov and Iliakis, 2011). Additional studies 
along the same lines using mutant Chinese hamster cells with defects in the DNA PKcs, Ku86 
or XRCC4 components of C-NHEJ, or in the XRCC2 and XRCC3 components of HR confirmed 
these observations (Wu et al., 2008). Wild-type cells and mutants of HR repaired DSBs with 
similar efficiency in G1 and G2 phases. Mutants of C-NHEJ, showed more pronounced repair 
in G2 phase than in G1. These results in aggregate demonstrate a new and potentially 
important cell cycle regulation of ALT-NHEJ and generate a framework to investigate the 
mechanistic basis of HR contribution to DSB repair and its possible interactions with ALT-
NHEJ.  
Yet another study by Shibata et al., also examined the regulation of repair pathway usage 
at DSBs in G2 (Shibata et al., 2011). They identified the speed of DSB repair as a major 
component influencing repair pathway usage showing that DNA damage and chromatin 
complexity are factors influencing DSB repair rate and pathway choice. They found that 
loss of C-NHEJ proteins slowed DSB repair allowing increased resection. In contrast, loss 
of HR does not impair repair by C-NHEJ although CtlP-dependent end-resection precludes 
C-NHEJ usage. These data suggest that C-NHEJ initially attempts the repair of DSBs and, if 
rapid rejoining does not ensue, then resection occurs promoting repair by HR using the 
homologous chromosome as template, but this may result in loss of heterozygosity (LOH). It 
is likely that if repair does not occur by HR, DNA ends will be repaired by error-prone 
pathways, such as SSA and ALT-NHEJ, pathways that require end-resected DSBs (Shibata et 
al., 2011) (Figure 2). 
2.2.3.2 Factors regulating ALT-NHEJ 
Unlike C-NHEJ, the mechanism(s) for regulation of ALT-NHEJ and the factors involved in 
this repair pathway(s) are not clearly understood. The presence of Ku proteins appear to 
determine whether DSBs are repaired by C-NHEJ vs. ALT-NHEJ (Bennardo et al., 2008, 
Fattah et al., 2010, Cheng et al., 2011). Fattah et al., utilized an end-joining assay in isogenic 
human colon carcinoma cell lines and human somatic HCT116 with targeted deletions of the 
key C-NHEJ factors (Ku, DNA PKcs, XLF, and DNA ligase IV). The end-joining assay was a 
plasmid based repair assay of a DSB made within reporter plasmid pEGFP-Pem1-Ad2 and 
reconstitution of green fluorescent protein (GFP). They found that absence of key C-NHEJ 
factors resulted in cell lines that were profoundly impaired in DSB repair activity. 
Unexpectedly, Ku86-deleted cells showed wild-type levels of DNA DSB repair activity but 
the events were mainly repaired by microhomology joining. Using siRNA technology, ALT-
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NHEJ repair activity could also be efficiently activated in DNA ligase IV-/- and DNA PKcs-/- 
cells by subsequently reducing the level of Ku70. Recently, Cheng et al., demonstrated that 
Ku is the main factor preventing PARP-1 and MRN mobilization to the site of DSBs (Cheng 
et al., 2011). These studies demonstrate that Ku proteins are the critical C-NHEJ factors that 
regulate DSB repair pathway choice. Similarly, studies of Bennardo et al., compared the 
genetic requirements for ALT-NHEJ, using a series of chromosome integrated reporters to 
monitor repair of DSBs by the I-SceI endonuclease in mouse embryonic stem (ES) cells and 
the HEK293 cell line (Bennardo et al., 2008). Each individual reporter was designed such 
that repair of I-SceI-induced DSBs by a specific pathway restored a GFP expression cassette. 
Such repair was then scored in individual cells as green fluorescence using flow cytometric 
analysis. They found that the Ku70-/- cells exhibited a 4-fold increase in the restoration of the 
GFP+ gene over wild-type cells, and that this increase was reversed by co-transfection of a 
Ku70 expression vector (Bennardo et al., 2008). Thus, the ALT-NHEJ repair events appeared 
not only to be Ku-independent, but also appear to be inhibited by Ku proteins (Bennardo et 
al., 2008, Cheng et al., 2011). Bennardo and Stark have also highlighted the importance of the 
presence of ataxia telangiectasia-mutated (ATM) in matching correct DNA ends during end-
joining and preventing the joining of multiple chromosome ends that can lead to chromosomal 
translocation and genomic instability (Bennardo and Stark, 2010). They found that genetic or 
chemical disruption of ATM caused a substantial increase in incorrect end joining (Distal-EJ), 
but not correct end joining (Proximal-EJ). Moreover, the increase in Distal-EJ caused by ATM 
disruption was dependent on the presence of C-NHEJ factors, specifically DNA PKcs, XRCC4, 
and XLF. Thus, these authors concluded that ATM is important to limit incorrect end 
utilization during C-NHEJ. In yet another study, Zha et al. showed that ATM and XLF have 
fundamental roles in processing and joining DNA ends during V(D)J recombination, but that 
these roles were masked by functional redundancies. They found that combined deficiency of 
ATM and XLF nearly blocked mouse lymphocyte development due to an inability to process 
and join chromosomal V(D)J recombination DSB intermediates. Combined XLF and ATM 
deficiency also severely impaired C-NHEJ, but not ALT-NHEJ, during CSR. Redundant ATM 
and XLF functions in C-NHEJ appeared to be mediated by ATM kinase activity and are not 
required for extra-chromosomal V(D)J recombination, indicating a role for chromatin-
associated ATM substrates. These authors also found a role for H2AX, protein involved in the 
recruitment of DNA repair factors to nuclear foci after DSBs (Rogakou et al., 1998). Conditional 
H2AX inactivation in XLF-deficient pro-B lines leads to V(D)J recombination defects associated 
with marked degradation of unjoined V(D)J ends, revealing that H2AX also has a role in the 
repair process (Zha et al., 2011). 
Mechanistically, it is believed that during ALT-NHEJ both broken ends are resected to 
generate 3′-single-stranded overhangs (Huertas, 2010). Given that Ku-deficiency can lead to 
elevated DSB end-processing, these results raise the possibility that ALT-NHEJ, SSA and HR 
share end-processing as a common intermediate. Thus, Bennardo et al., determined also 
whether end-resecting factor CtlP is important for ALT-NHEJ, by performing siRNA knock-
down of CtlP in HEK293 cell lines with integrated GFP reporter plasmids and stable 
expression of the inducible I-SceI protein and examined ALT-NHEJ repair in CtlP-depleted 
cells vs. control cells. They observed that ALT-NHEJ was significantly reduced in CtlP-
depleted cells suggesting that CtlP-mediated DSB end-processing promotes ALT-NHEJ but 
also SSA and HR (Bennardo et al., 2008). Interestingly, disrupting RAD51 and RAD52 
expression decrease HR and SSA activity respectively without perturbing ALT-NHEJ repair 
www.intechopen.com
 
DNA Repair and Human Health 100 
(Bennardo et al., 2008). In recent studies, Zhang and Jasin, showed that depletion of CtlP, 
resulted in a substantial decrease in the chromosomal translocation frequency in mouse cells 
and a significantly lower usage of microhomology at the translocation breakpoint junctions. 
This suggests that CtlP-mediated ALT-NHEJ has a primary role in translocation formation 
(Zhang and Jasin, 2011).  
Several studies have also implicated the MRN complex in ALT-NHEJ repair (Rass et al., 
2009, Xie et al., 2009). Recent studies examined the role of the nuclease MRE11 in CSR. They 
showed that loss of the nuclease MRE11 resulted in milder defects, compared with loss of 
the whole MRN complex. This suggested that the MRN complex performed activities in 
end-joining, in addition to the nuclease activity of MRE11. Studies employing atomic force 
microscopy have visualized the MRN complex bridging DNA at distances of 1200 
angstroms (Moreno-Herrero et al., 2005). Thus, MRN may perform bridging functions that 
may be particularly suited for CSR. In addition, since chromosomal translocations are 
frequently observed in ALT-NHEJ, the MRN complex may also play a role in end-bridging 
of distant DSBs, resulting in chromosomal rearrangements (Figure 2).    
A schematic representation of the regulation and the hierarchy of the DSB repair pathways 
is presented in Figure 2. 
 
 
Fig. 2. The majority of the DSBs are repaired by C-NHEJ. If this pathway is inactive, DSBs 
can be repaired by HR using the homologous chromosome as template or by SSA or ALT-
NHEJ. Positive regulators of specific stage as described in text are represented in blue while 
defective pathways are represented in red.  
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2.2.4 ALT-NHEJ at dysfunctional telomeres 
Mammalian telomeres are regions of repetitive DNA sequences at the ends of chromosomes, 
which protect them from e or from fusion with neighbouring chromosomes. Critically 
shortened telomeres are recognized as DSBs and are highly susceptible to be repaired by HR 
or NHEJ pathways (Palm et al., 2009, Rai et al., 2010). However, unequal exchange of 
telomeric sequences by HR or misrepair by C- and/or ALT-NHEJ, can lead to loss of cell 
viability or can result in genomic instability and cancer. In mammals, telomeres form single-
stranded G-rich overhangs that associate with and are protected by shelterin, a core complex 
of telomere-binding proteins that includes the double-stranded DNA-binding proteins TRF1 
and TRF2 and protection of telomeres 1 (POT1a/b) that interacts with its binding partner 
TPP1 to protect them from resection, recombination and alteration (Palm et al., 2009). 
Telomeres are maintained by the enzyme telomerase, which is limited in human somatic 
cells, resulting in progressive telomere shortening. Celli et al., showed that Ku and TRF2 
repress HR and represent an important aspect of telomere protection (Celli et al., 2006). 
Recent evidence suggests that dysfunctional telomeres that can no longer exert end-protective 
functions are recognized as DSBs by the DNA damage repair pathway. Thus, removal of TRF2 
with retrovirus-mediated shTrf2, resulted in end-to-end chromosome fusions mediated by the 
C-NHEJ pathway (Rai et al., 2010). In addition, the data of Deng et al., indicated a critical role 
for the MRN complex in sensing these dysfunctional telomeres. They showed that in the 
absence of TRF2, MRE11 nuclease activity removes the 3' telomeric overhang to promote 
chromosome fusions. MRE11 can also protect newly replicated leading strand telomeres from 
NHEJ by promoting 5' strand resection to generate POT1a-TPP1-bound 3' overhangs (Deng et 
al., 2009). Rai et al. used also MEFs in which specific components of the C-NHEJ had been 
deleted to determine how dysfunctional telomeres are joined together (Rai et al., 2010). They 
showed that DSB marker 53BP1 (Schultz et al., 2000, Anderson et al., 2001) was necessary for 
end to end fusion in TRF2 deficient MEFs. Surprisingly, they showed that removal of Tpp1-
Pot1a/b from 53BP1-/- MEFs or DNA ligase IV-/- MEFs resulted in robust end to end fusions. They 
also examined chromosome fusion in MEFs from telomerase knock-out cells that generate 
naturally shortened telomeres, and which had also been knocked out for 53BP1-/-. Lymphomas 
derived from these mice demonstrated an increase in the number of fused chromosomes. 
These data suggested that fusion of naturally shortened telomeres do not require 53BP1 and 
occur through mechanisms independent of C-NHEJ. They concluded that telomeres engage 
distinct DNA repair pathways depending on how they are rendered dysfunctional, and that 
ALT-NHEJ is a major pathway for processing of dysfunctional telomeres (Rai et al., 2010).  
2.2.5 NHEJ-defective mouse models of cancers and leukemias  
2.2.5.1 NHEJ in V(D)J recombination and CSR 
In addition to DSBs generated by exogenous and endogenous DNA damaging agents, DSBs 
also occur as a consequence of specific physiological processes such as the V(D)J 
recombination in B and T-lymphocytes and the immunoglobulin CSR within 
immunoglobulin variable domains in B-lymphocytes during the development and 
maturation of the immune system (Ferguson and Alt, 2001, Revy et al., 2005). The organism 
recruits stringent DNA repair machinery to ensure the efficient repair of the damage or the 
elimination of the damaged cells. Failure to properly repair the DNA damage may cause 
chromosomal abnormalities, which in turn may lead to genomic instability and predispose 
the cells to malignant transformation. 
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The immune system provides a unique platform for understanding the NHEJ pathway 
because of its requirement for V(D)J recombination and CSR for development and 
maturation. In these systems, DNA damage is initiated by recombination activating gene 1 
and 2 (RAG1/RAG2) in the case of V(D)J recombination, activation-induced cytidine 
deaminase (AID) in the case of CSR (Oettinger et al., 1990, McBlane et al., 1995, Petersen et 
al., 2001, Manis et al., 2002), that is uniquely expressed in specialized B- or T-lymphocytes. 
The rejoining of the broken DNA ends is then completed by C- and/or ALT-NHEJ pathway 
(Bassing et al., 2002). Notably, V(D)J recombination specifically recruits the C-NHEJ 
pathway components (Corneo et al., 2007). In contrast, approximately 50% of CSR events 
are completed by the ALT-NHEJ pathways (Soulas-Sprauel et al., 2007b, Yan et al., 2007, 
Han and Yu, 2008). Animal models and human conditions have demonstrated that defects 
in any of the C-NHEJ pathway components may cause immunodeficiency. The resultant 
erroneous DNA repair may predispose the cells to genomic instability and the 
development of cancer.  
2.2.5.2 Defective C-NHEJ in immunodeficiency  
Spontaneous mutant and genetically engineered animal models deficient for the various C-
NHEJ components have in common impaired V(D)J recombination and consequent 
immunodeficiency, together with increased sensitivity to ionizing radiation. 
Severe combined immune deficiency (SCID) mouse is a naturally occurring mutant mouse 
strain (Bosma and Carroll, 1991) which harbors a non-sense mutation in their highly 
conserved C-terminal part of DNA PKcs gene (Blunt et al., 1996, Araki et al., 1997). These 
mice lack mature B and T lymphocytes (Bosma and Carroll, 1991), accompanied by an 
increased cellular radiosensitivity (RS-SCIDs), indicative of a defect in DNA repair. 
Similarly, DNA PKcs knockout mice do not show overt cellular growth defects but exhibit 
immunodeficiency and ionizing radiation hypersensitivity (Gao et al., 1998, Taccioli et  
al., 1998, Kurimasa et al., 1999). Artemis-deficient mice resemble DNA PKcs-deficient mice, 
including a leaky SCID and increased cellular ionizing radiation sensitivity, supporting the 
idea that Artemis cooperates with DNA PKcs in a subset of C-NHEJ functions (Rooney et al., 
2002).  
Like the DNA-PKcs mutant SCID mice, Ku70 and Ku86 knockout mice demonstrate “leaky” 
immunodeficiency and are hypersensitive to irradiation (Nussenzweig et al., 1996, Zhu et al., 
1996, Gu et al., 1997, Ouyang et al., 1997). In addition, they also show signs of growth 
retardation and extensive apoptosis of the newly generated neurons. Mice lacking either 
XRCC4 or DNA ligase IV die in utero with massive neuronal apoptosis and a complete block in 
lymphocyte development, suggesting the requirement for Ku, XRCC4 and DNA ligase IV in 
growth control and neuron development (Barnes et al., 1998, Frank et al., 1998, Gao et al., 
1998). Mice lacking XLF are also immunodeficient and hypersensitive to ionizing radiation. 
However, they have modestly reduced lymphocyte numbers, nearly normal V(D)J 
recombination and moderately defective immunoglobulin heavy chain CSR (Li et al., 2008). 
Combined deficiency of ATM and XLF severely impairs V(D)J recombination and nearly 
blocks mouse lymphocyte development, indicative of the compensatory roles of ATM and XLF 
in C-NHEJ pathway (Zha et al., 2011), as discussed earlier in this chapter. 
2.2.5.3 Involvement of ALT-NHEJ pathways in leukemia/lymphoma in mouse models 
In the absence of C-NHEJ, the microhomology-based ALT-NHEJ is thought to be employed 
to ligate the broken DNA ends generated during V(D)J recombination and CSR.  
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Mice defective for one or more C-NHEJ components show various degrees of genomic 
instability. The absence of Ku, XRCC4, DNA ligase IV, XLF, Artemis, or DNA PKcs leads to 
the accumulation of DNA breaks and translocations in ES cells, fibroblasts or stimulated B 
cells (Guidos et al., 1996, Nacht et al., 1996, Karanjawala et al., 1999, Difilippantonio et al., 
2000, Ferguson and Alt, 2001, Zhu et al., 2002, Rooney et al., 2003, Yan et al., 2007, Franco et 
al., 2008, Li et al., 2008, Boboila et al., 2010a). In the presence of the p53-null background, 
deletion of any one of the key components of the C-NHEJ pathway invariably leads to the 
early onset of very aggressive tumors, mostly pro-B-cell lymphomas, which generally 
harbor chromosomal translocations. Mice defective for P53 and Ku86 develop pro-B-cell 
lymphoma at an early age (Difilippantonio et al., 2000). These tumors display a specific set 
of chromosomal translocations and gene amplifications involving the immunoglobulin 
heavy chain IgH/Myc locus, reminiscent of Burkitt lymphoma. Combined deficiency in 
p53/XRCC4 or p53/DNA ligase IV results in live births. However, the offspring are 
immunodeficient and develop pro-B cell lymphomas (Frank et al., 2000, Gao et al., 2000). 
Mice lacking both Artemis and p53 develop pro–B cell lymphomas harboring N-myc-IgH, 
but not the Myc-Igh translocations observed in tumors in other C-NHEJ/p53 deficient mice 
(Rooney et al., 2004). XLF/p53-double-deficient mice are not markedly prone to pro-B 
lymphomas. However, like other C-NHEJ/p53-deficient mice, they still develop 
medulloblastomas (Li et al., 2008). 
Recent studies based on C-NHEJ deficient mutant models also revealed that Ku or DNA 
ligase IV/XRCC4 are not required for, but rather suppress chromosomal translocations 
(Corneo et al., 2007, Soulas-Sprauel et al., 2007a, Yan et al., 2007, Boboila et al., 2010a). It has 
recently been reported that translocation breakpoint junctions are similar in wild-type and 
Ku or XRCC4 deficient mutants, including an unchanged bias toward microhomology. 
Complex insertions at some breakpoint junctions show that joining can be iterative, 
encompassing successive processing steps before joining, implying that ALT-NHEJ 
contributes to the translocation formation in mammalian cells (Simsek and Jasin, 2010).  
Altogether, the development of leukemia/lymphoma in C-NHEJ deficient mouse models 
suggests that ALT-NHEJ pathways play important roles in the DSB repair in V(D)J 
recombination and CSR. Its low fidelity predisposes the cells to genomic instability and the 
development of malignancy. Further investigations of the molecular mechanisms 
underlying these pathways will provide insights into the roles of ALT-NHEJ in the 
occurrence of genomic instability and the development of cancer.  
2.2.6 ALT-NHEJ in human cancer and leukemia 
Many of the studies characterizing ALT-NHEJ have been conducted in a background of 
experimentally induced deficiency of components of the C-NHEJ pathway. This has drawn 
criticism that the results demonstrating ALT-NHEJ are biased by artificial experimental 
conditions that do not exist in reality. Many human cancers are characterized by recurrent 
chromosome abnormalities and microhomologous sequences have been identified at the 
breakpoint junctions of these abnormalities. Therefore, human cancers may represent model 
systems in which to study ALT-NHEJ. 
2.2.6.1 Leukemia and lymphoma cells as models for the study of ALT-NHEJ 
Like the SCID phenotype observed in mice, defective V(D)J recombination in humans causes 
arrest of B and T lymphocyte maturation, conferring severe combined immune deficiency 
(T-B-SCID).  70% of T-B-SCID patients have mutations in RAG1 or RAG2, which disables the 
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initiation steps in V(D)J recombination. The remaining 30% patients also show 
hypersensitivity to ionizing radiation, and therefore referred to as RS-SCID. They are caused 
by defects in the C-NHEJ pathway (de Villartay et al., 2003). So far, most genetic defects 
reported are found in the Artemis gene. In other cases, mutations in DNA ligase IV, XLF and 
DNA PKcs are reported. EBV-associated B-cell lymphomas and leukemia have been 
reported in patients with Artemis and DNA ligase IV mutations, respectively, indicative of 
the genomic instability associated with the impaired C-NHEJ (Riballo et al., 1999, Moshous 
et al., 2003). Patients with mutations in the gene encoding XLF also have greater 
chromosomal instability (Dai et al., 2003, Buck et al., 2006). These findings suggest that RS-
SCID patients defective for C-NHEJ have elevated genomic instability which may 
predispose the cells to cancer. It is also likely that ALT-NHEJ among other error-prone 
pathways may drive genomic instability in these cases.   
2.2.6.2 Microhomologies at breakpoints junction of recurrent alterations in cancer and 
leukemia 
In vivo and in vitro assays in cancer and leukemia cells demonstrate increased errors 
following repair, with the majority of errors resulting from large DNA deletions occurring at 
the repair sites characterized by sequence microhomologies. Using in vitro end-joining 
assays based on repair of pUC18 plasmids containing a DSB in cell lines derived from 
myeloid leukemias, Gaymes et al. demonstrated a significant increase in errors characterized 
by increased size of deletions and microhomologies at the repair junctions further 
suggestive of the importance of ALT-NHEJ repair in these malignancies (Gaymes et al., 
2002). Analyzing actual genomic deletions in tumors, Canning and Dryja found genomic 
deletions involving the retinoblastoma gene in 12 of 49 tumors from patients with 
retinoblastoma or osteosarcoma. They mapped the deletion breakpoints and sequenced 200 
base pairs surrounding each deletion breakpoint in DNA from 4 tumor samples. Three 
deletions had termini characterized by direct repeats ranging in size from 4 to 7 base pairs 
(Canning and Dryja, 1989).  
Recurrent chromosome translocations characterize leukemia and lymphoma and are 
specifically associated with their classification and prognosis. They occur frequently in 
both de novo and therapy-related in acute myeloid leukemia (AML) and myelodysplastic 
syndromes (MDS). Cloning of the genomic breakpoints in the common chromosome 
translocations in leukemia reveal that most of the genomic breakpoints tend to cluster in a 
restricted intronic region (Zhang and Rowley, 2006). In addition, sequencing of the 
translocation junctions identified regions of microhomology, strongly indicative of the 
involvement of ALT-NHEJ in the repair of DSBs and the generation of these chromosomal 
abnormalities (Reichel et al., 1998, Gillert et al., 1999, Strissel et al., 2000, Rassool, 2003, 
Zhang and Rowley, 2006; Wiemels and Greaves, 1999, Xiao et al., 2001, Reiter et al., 2003, 
Zhang and Rowley, 2006). An important example of such a study is sequencing of the TEL 
AML1 gene fusions found in pediatric leukemias and approximately 25% of adult acute B 
cell lymphomas. Analysis of the DNA sequence and structure surrounding the breakpoints 
revealed clues to their possible formation (Wiemels and  Greaves, 1999). A long-distance 
inverse PCR strategy was used to amplify TEL-AML1 genomic fusion sequences from 
diagnostic DNA from nine patients. Breakpoints were scattered within the 14 kb of intronic 
DNA between exons 5 and 6 of TEL and in two putative cluster regions within intron 1 of 
AML1. DNA sequences containing the breakpoint junctions exhibited characteristic signs of 
C- and ALT-NHEJ, including microhomologies at the breakpoints, small deletions and 
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duplications. Wiemels and Greaves concluded that the data was compatible with the 
possibility that TEL-AML1 translocations occur by nonhomologous recombination involving 
imprecise, constitutive repair processes following DSBs (Wiemels and Greaves, 1999, Zelent 
et al., 2004).  
2.2.6.3 Origins of DNA damage? 
Genes such as AML1, TEL or mixed lineage leukemia (MLL) have been found rearranged with 
different partner genes in lymphoid and myeloid leukemias (Zelent et al., 2004). These 
translocations have been shown to correlate with sites of double-strand DNA cleavage by 
agents to which the cells or patients have been exposed, including exogenous rare-cutting 
endonucleases, radiomimetic compounds, and topoisomerase inhibitors (Greaves and 
Wiemels, 2003). The nature of the DNA damage leading to MLL translocations in leukemia 
in infants have been examined by several investigators (Greaves and Wiemels, 2003). The 
finding of identical MLL rearrangements in the leukemias from pairs of monozygotic twins 
where both twins were affected, but not in their constitutional DNA, established that MLL 
translocations in infant leukemias are non-hereditary, non-constitutional, in utero events. 
Furthermore, the most likely explanation was that cells with the translocation were 
transferred from one twin to the other via the placenta (Felix et al., 2000). The retrospective 
finding of leukemia-associated MLL genomic breakpoint junction sequences by PCR 
analysis of genomic DNAs contained in bloodspots on neonatal Guthrie cards of infants 
who were diagnosed later with leukemia showed that MLL translocations also occur in utero 
in the non-twin cases (Gale et al., 1997). Molecular cloning and analysis of MLL genomic 
breakpoint junctions sequences in infant leukemias suggested staggered and/or multiple 
sites of breakage as elements of damage and DNA repair by C- and/or ALT-NHEJ. This 
provided further evidence that DNA damage and repair underlie the formation of the 
translocations (Greaves and Wiemels, 2003, Gilliland et al., 2004). Because MLL 
translocations are much less frequent in de novo leukemias of older patients but frequent in 
leukemias following chemotherapeutic DNA topoisomerase II poisons, e.g., etoposide, it has 
been proposed that leukemia in infants may have an etiology resembling treatment-related 
cases (Gilliland et al., 2004). The chemotherapy-leukemia association in the treatment-
related cases suggests that chromosomal breakage resulting from DNA topoisomerase II 
cleavage and attempted repair of DSBs may play a role in the formation of these 
translocations. The precision of the breakpoint junction sequences and the results of DNA 
topoisomerase II in vitro cleavage assays in treatment-related leukemias are consistent 
with the processing of 4-base, staggered DSB (Gilliland et al., 2004). In the infant 
leukemias, the breakpoint junction sequences and in vitro cleavage assays suggest a 
mechanism in which DNA topoisomerase II introduce separate single-stranded nicks in 
duplex DNA that are staggered by up to several hundred bases. This leads to a DNA 
damage-repair model in which various naturally occurring DNA topoisomerase II poisons 
induce DNA topoisomerase II-mediated damage in leukemia in utero (Gilliland et al., 2004). 
The large deleted regions observed in other infant cases are consistent with multiple sites 
of breakage or, alternatively, more extensive processing (Raffini et al., 2002). 
2.2.6.4 Increased ALT-NHEJ activity in leukemia  
In addition to increased DNA damage providing a substrate for error-prone repair and 
genomic instability, increased repair activity may also drive the acquisition of genomic 
alterations. Recently, Sallmyr at al. demonstrated increased activity of the ALT-NHEJ 
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pathway in chronic myeloid leukemia (CML) cells characterized by the oncogenic fusion 
tyrosine kinase, BCR-ABL (Gaymes et al., 2002, Sallmyr et al., 2008b). They showed that key 
proteins in the major C-NHEJ pathway, Artemis and DNA ligase IV, were down-regulated, 
whereas DNA ligase IIIα, and the protein deleted in Werner syndrome, WRN, are up-
regulated in CML cells. Furthermore, they showed that DNA ligase IIIα and WRN form a 
complex that is recruited to DSBs, and that “knockdown” of either DNA ligase IIIα or WRN 
leads to increased accumulation of unrepaired DSBs, demonstrating that these DNA repair 
proteins contribute to their repair. To determine whether knockdown of either DNA ligase 
IIIα or WRN leads to differences in repair using DNA sequence microhomologies, Sallmyr et 
al. sequenced the breakpoint junctions of 15 repaired plasmids from each of the LacZα 
reactivation experiments. The majority (80%) of plasmids in CML cell line, K562 were 
repaired using DNA microhomologies of 1 to 6 bp. In contrast, plasmids from cells with 
reduced levels of either DNA ligase IIIα or WRN had a reduction in the overall percentage 
of microhomologies and these constituted 1 to 3 bp in length (DNA ligase IIIα, 25%; WRN, 
40%) at the breakpoint junctions in repaired plasmids. Notably, in cell lines established from 
normal lymphocytes, end-joining assays reveal that the DSBs are repaired mainly using the 
C-NHEJ pathway. Furthermore, sequencing of the rare DSBs that were misrepaired (1 in 
approximately 10,000) revealed deletions of only a few base pairs. These results indicate that 
while ALT-NHEJ is possibly operative at very low levels in normal cells, altered DSB repair 
in CML cells may be caused at least in part by the increased activity of ALT-NHEJ repair 
pathway, involving DNA ligase IIIα and WRN. In AML characterized by expression of the 
constitutively activated receptor tyrosine kinase Fms Like tyrosine 3/Internal tandem 
duplication (FLT3/ITD), Sallmyr et al. reported that this constitutively activated tyrosine 
kinase initiates a cycle of genomic instability that is likely to promote both aggressive 
disease and resistance to therapy (Sallmyr et al., 2008a). Specifically, Sallmyr et al. showed 
that expression of FLT3/ITD induces increased reactive oxygen species production and that 
cells transformed by FLT3/ITD, including primary AML cells and cell lines established from 
FLT3/ITD-positive AML patients, have increased endogenous DSBs (Sallmyr et al., 2008a). 
Furthermore, repair of DSBs by NHEJ is less efficient and more error-prone in FLT3/ITD-
expressing cells (Sallmyr et al., 2008a). More recently, Fan et al. reported that the steady state 
levels of Ku86 and to a lesser extent, Ku70, are significantly reduced in FLT3/ITD-
expressing cells (Fan et al., 2010). In turn, there is a concomitant increase in the steady state 
levels of ALT-NHEJ components, PARP-1 and DNA ligase IIIα (Fan et al., 2010). Similar 
alterations in Ku86 and PARP-1 are also observed in FLT3/ITD knock-in mice, but increased 
levels of DNA ligase IIIα are only seen in the homozygote mice (Fan et al, 2010). Similar 
changes in C-NHEJ and ALT-NHEJ components are observed at the transcript level (Li et al., 
2011) (Figure 3). In the FLT3/ITD mouse model, the impairment of C-NHEJ decreases the 
ability of cells to complete post-cleavage DSB ligation, resulting in failure to complete V(D)J 
recombination inhibiting B-lymphocyte maturation (Li et al, 2011). As a consequence of these 
changes in NHEJ proteins, the frequency of DNA sequence microhomologies and the size of 
deletions at repair sites are increased, reflecting the increased contribution of ALT-NHEJ to 
DSB repair. This suggests that FLT3/ITD signaling is involved in regulating both C- and ALT-
NHEJ, directly or indirectly (Figure 3). Importantly, they reported that reducing the levels of 
DNA ligase IIIα in AML cells not only reduces the frequency of DNA sequence 
microhomologies and the size of deletions at repair sites but also increases the steady state 
levels of unrepaired DSBs, indicating that the ALT-NHEJ pathway is particularly important 
for the survival of FLT3/ITD expressing AML cells (Li et al., 2011).   
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2.2.7 ALT-NHEJ as therapeutic targets  
Several lines of evidence suggest that both hereditary and sporadic cancers have abnormal 
level of DNA damage and repair responses that lead to the generation of structural 
chromosomal abnormalities and genomic instability, which are critical for survival, disease 
progression and resistance. The identification of defects in the DNA damage response 
between normal and cancer cells at the molecular level will guide the development of more 
targeted therapies by identifying biomarkers that are indicative of the abnormal DNA repair 
in cancer cells. To exploit the differences in the DNA damage response between normal and 
cancer cells, it will be necessary to characterize the DNA repair abnormalities and develop 
agents that target the abnormal DNA repair pathways that are specific for cancer cells, 
thereby reducing survival of cancer but not normal cells. In addition to participating in base 
excision and SSB repair, PARP-1 and DNA ligase IIIα also appear to be involved in ALT-
NHEJ. In recent studies, we and others have shown that PARP-1 and DNA ligase IIIα are 
upregulated in certain cancers and leukemias (Chen et al., 2008, Sallmyr et al., 2008b, Fan et 
al., 2010, Li et al., 2011) (Figure 4).  
 
 
Fig. 3. Schematic for the mechanism of regulation of C- and ALT-NHEJ by FLT3/ITD. 
FLT3/ITD signalling leads to upregulation of DNA ligase IIIα and PARP-1 and 
downregulation of Ku70/86. The consequent increase in ALT-NHEJ activity promotes the 
acquisition of genomic changes that lead to disease progression or resistance to treatment.   
2.2.7.1 PARP inhibitors 
The abundant nuclear protein PARP-1 binds avidly to SSBs, an event that activates PARP-1 
polymerase (Ame et al., 2004). Activated PARP-1 utilizes nicotinamide to synthesize 
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poly(ADP-ribose) polymers on itself and other nuclear proteins. Poly(ADP-ribosylated) 
PARP-1 serves as a recruitment factor for DNA ligase IIIα/XRCC1 and other factors 
involved in the repair of SSBs (Okano et al., 2003). Although there are other PARP family 
members, PARP-1 is the predominant enzyme that synthesizes poly(ADP-ribose) in 
response to DNA damage (Menissier de Murcia et al., 2003). The replication of DNA 
containing SSBs cause DSBs and so preventing the repair of SSBs by inhibiting PARP-1 
results in an increase in DSBs. Since these replication-associated DSBs would normally be 
repaired by HR, cells that are defective in HR are hypersensitive to PARP inhibitors. Based 
on this rationale, potent and specific inhibitors of PARP were developed as therapeutic 
agents for inherited forms of breast and ovarian cancer as the PARP inhibitors should be 
cytotoxic for BRCA mutant tumors but not normal tissues with a functional BRCA allele 
(Bryant et al., 2005, Farmer et al., 2005). As expected, PARP inhibitors increased the 
cytotoxicity of a range of anti-cancer agents including temozolomide and ionizing radiation 
that cause SSBs (Tentori et al., 2002, Liu et al., 2008) and both BRCA1- and BRCA2-mutant 
cell lines were hypersensitive to PARP inhibitors in cell culture and mouse xenograft assays 
(Lord and Ashworth, 2008). These results formed the basis for a phase I clinical trial, which 
demonstrated that the PARP inhibitor AZD2281 exhibited antitumor activity in patients 
with ovarian and breast tumors resulting from either BRCA1 or BRCA2 mutations (Evers et 
al., 2008). The promising results from this clinical trial have prompted the evaluation of 
PARP inhibitors in combination with other cancer therapeutics in the treatment of different 
types of cancer.    
Unfortunately, resistance to PARP-1 inhibitors has led to the failure of phase III clinical trials 
in triple negative breast cancers, and thus there is an urgency for elucidating the 
mechanisms by which resistance occurs in cells with defects in HR (Guha, 2011). One 
potential mechanism for resistance to PARP inhibitors in BRCA-deficient cells is that 
spontaneous or induced DSBs are rerouted for repair by error-prone mechanisms, including 
NHEJ, because the preferred mode of error-free repair by HR is unavailable (Venkitaraman, 
2001). Patel et al. recently showed that in BRCA2 deficient ovarian cancer cell lines PARP 
inhibitor treatment induces phosphorylation of DNA PK substrates and stimulates C-NHEJ 
selectively. Previous studies provided evidence for interplay between key C-NHEJ proteins 
and PARP-1: (i) PARP-1 can interact in vitro and in vivo with Ku (Galande and Kohwi-
Shigematsu, 1999) and has been shown to compete with Ku80 for DNA ends in vitro (Wang 
et al., 2006), (ii) Ablation of C-NHEJ restores the survival of PARP-1-deficient cells treated 
with agents inducing DSBs (Hochegger et al., 2006). All together those results suggest that 
C-NHEJ and perhaps ALT-NHEJ could be involved in the genomic instability observed in 
HR-deficient cells treated with PARP inhibitors (Patel et al., 2011). Patel et al. showed that 
inhibiting DNA PK activity reverses the genomic instability induced by PARP inhibition in 
BRCA2 deficient cells. Moreover, disabling C-NHEJ by using genetic or pharmacologic 
approaches diminished the toxicity of PARP inhibition in HR-deficient cells. These results 
not only implicate PARP-1 catalytic activity in the regulation of C-NHEJ and perhaps ALT-
NHEJ in HR-deficient cells, but also indicate that deregulated C-NHEJ and perhaps ALT-
NHEJ plays a major role in generating cytotoxicity and genomic instability in HR-deficient 
cells treated with PARP inhibitors (Patel et al., 2011). Recently Chen et al. showed that C-
NHEJ protein DNA ligase IV was down regulated in cell lines derived from sporadic breast 
cancer (Chen et al., 2008). Thus, it would be important to evaluate C-NHEJ and ALT-NHEJ 
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2.2.7.2 DNA ligase inhibitors 
DNA joining events are required for the completion of almost all DNA repair pathways. 
Thus, inhibitors of DNA ligase are predicted to sensitize cells to a variety of DNA damaging 
agents depending upon the inhibitor specificity for the three mammalian DNA ligases. 
Using computer-aided drug design based on the structure of human DNA ligase I in 
complex with nicked DNA, a series of small molecule inhibitors of human DNA ligases have 
been identified (Chen et al., 2008, Zhong et al., 2008). Briefly, an in silico data base of about 
1.5 million commercially available small molecules was screened for candidates that were 
predicted to bind to a DNA binding pocket within the DNA binding domain (DBD) of 
human DNA ligase I. This binding pocket makes key contacts with nicked DNA (Chen et al., 
2008). Out of 233 candidate molecules, 192 were assayed for their ability to inhibit human 
DNA ligase I but not T4 DNA ligase and for their ability to inhibit cell proliferation because 
human DNA ligase I is the major replicative DNA ligase. The in vitro DNA joining assays 
identified 10 small molecules that specifically inhibit human DNA ligase I by more than 50% 
at 100 mM, with 5 of these molecules also inhibiting the proliferation of cultured human 
cells. Since the amino acid sequences of the DBDs of human DNA ligases III and IV are 
closely related to that of the human DNA ligase I DBD, Chen et al. enquired whether the 
inhibitors of human DNA ligase I are also active against the other human DNA ligases. 
Molecules that inhibit DNA ligase I alone (L82), DNA ligase I and III (L67), and all three 
human DNA ligases (L189) in vitro, that were also active in cell culture assays, were 
further characterized. In accord with the screening strategy, all the ligase inhibitors with 
the exception of L82 act as competitive inhibitors with respect to nicked DNA. The 
structure of L67 and the other inhibitors consists of heterocyclic rings separated by a 
flexible linker. Interestingly, L67 and L189 are cytotoxic, whereas L82 is cytostatic. It is 
possible that this reflects the different mechanisms of inhibition. Alternatively, while 
inhibition of DNA ligase I alone is not toxic, inhibition of either DNA ligase III or DNA 
ligase IV alone or in combination with human DNA ligase I may be cytotoxic. Another 
interesting feature of the ligase inhibitors is that sub-toxic concentrations specifically 
potentiate the cytotoxicity of DNA-damaging agents in cancer cells (Figure 4). As in cell 
lines expressing BCR-ABL and FLT3/ITD (Sallmyr et al., 2008b, Fan et al., 2010), DNA 
ligase IIIα is also overexpressed in cancer cell lines, whereas the levels of DNA ligase IV 
are reduced compared to a non-cancerous breast epithelial cell line (Chen et al., 2008). 
Together these results suggests that ligase inhibitors will not only provide a novel 
approach to delineating the cellular functions of these enzyme, but may also serve as lead 
compounds for the development of therapeutic agents that target DNA replication and/or 
repair (Chen et al., 2008).  
Notably, these compounds exhibit different specificities for the three human DNA ligases in 
vitro and a subset of these molecules preferentially sensitize cancer cells to DNA alkylating 
agents and ionizing radiation, suggesting that they may have utility as lead compounds for 
the development of novel therapeutic agents. Notably, the ligase inhibitors would constitute 
an extremely versatile group of agents in that, depending on their specificity, they can be 
used to target a variety of DNA repair pathways that would be chosen based on the DNA 
damaging agent.  For example, a DNA ligase IV specific inhibitor would sensitize cells with 
a functional C-NHEJ pathway to ionizing radiation whereas a DNA ligase III specific 
inhibitor would sensitize cancer cells that are dependent upon ALT-NHEJ to ionizing 
radiation and other agents that cause DSBs, such as PARP inhibitors (Figure 4). 
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Fig. 4. Schematic of the effect of DNA ligase and PARP inhibitors on base excision repair, 
DNA replication and ALT-NHEJ in cancer and leukemia cells.  
3. Conclusion  
ALT-NHEJ is involved in the development of a variety of cancers, including leukemias, and 
is likely to play a key role in the generation of chromosomal abnormalities, including 
translocations, that drive cancer progression. It appears that cancer cells are more dependent  
on ALT-NHEJ for the repair of DSBs and survival, compared with normal cells. Thus 
targeting this pathway may be an attractive therapeutic strategy. Elucidation of the 
pathways components, and how they are regulated, will further guide the design of these 
therapies. Finally, investigation of the molecular mechanisms underlying abnormal DNA 
damage and repair in cancers and leukemias, together with the development of new animal 
models, will better our understanding of the complex relations between DNA repair and 
neoplastic transformation, which will provide new targets for the treatment of cancer. 
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